The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents

Psychopharmacology

Volumn 220, Issue 3, 2012, Pages 639-641

  Podobnik, Josip ^a   Podobnik, Iris Foller ^a   Grgic, Neda ^a   Marcinko, Darko ^b   Pivac, Nela ^c  

^a Psychiatric Hospitalfor children and adolescents   (Croatia)

^b KBC Zagreb   (Croatia)

^c RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; QUETIAPINE; SERTRALINE;

ADD ON THERAPY; ADOLESCENT; AGGRESSION; BIPOLAR DISORDER; BORDERLINE STATE; CHILD; CHILDREN GLOBAL ASSESSMENT SCALE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; IRRITABILITY; KUTCHER ADOLESCENT DEPRESSION SCALE; LETTER; MALE; MENTAL INSTABILITY; OVERT AGGRESSION SCALE MODIFIED; PRIORITY JOURNAL; PSYCHOSIS; SCHOOL CHILD; SCORING SYSTEM; SOMNOLENCE; SUICIDAL BEHAVIOR; TREATMENT DURATION; XEROSTOMIA;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CHILD; DEPRESSION; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; HUMANS; IRRITABLE MOOD; MALE; PILOT PROJECTS; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84858438930     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2607-7     Document Type: Letter

References (7)

1. Abraham PF, Calabrese JR (2008) Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111:21-30
2. Adityanjee RA, Brown E, Thuras P, Lee S, Schulz SC (2008) Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 20:219-226
3. Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM (2006) The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 16:665-670 (Pubitemid 46175422)
4. DeHert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Neuropsychopharmacol 21:144-158
5. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM (2009) A double-blind, placebo-controlled pilot study of que-tiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11:483-493
6. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, Mcnamara NJ (2007) A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol 17:1-9 (Pubitemid 46452077)
7. Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsycho-pharmacol 21:600-620